Skip to main content

Advertisement

Table 1 Baseline characteristics of the nine included studies

From: Feasibility of ipsilateral lower neck sparing irradiation for unilateral or bilateral neck node-negative nasopharyngeal carcinoma: systemic review and meta-analysis of 2, 521 patients

First author /year Time range Design No. of patients (ILNSI/ ILNPI) Matching itemsa Method of assessing LN metastasis N category Histologic type (WHO) Clinical stage Median FU (range), mo. Score
Li/2013 [27] 2005–2012 RCT 153/148 1, 2, 4, 9 MRI/CT N0 II-III I-IVa (AJCC 6th) 39.0 (6.0–84.0) RCT
Chen/2014 [26] 2003–2007 R 54/100 1, 2, 4, 6, 8, 10 MRI N1 I-II II-IVa (AJCC 7th) 60.7 (12.2–98.9) 8
Xie/2010 [30] 2002–2004 R 88/117 1, 2, 4, 10 CT/MRI/PET/ CT N0 NR I-Iva (UJCC 6th) 44.0 (3.0–68.0) 8
Ou/2012 [29] 2005–2009 R 89/30 1, 2, 3, 7, 9, 10 MRI N0 I-II I-IV (AJCC 6th) 36.6 (8.1–76.9) 9
Tang/2017 [24] 2009–2012 R 189/357 1, 2, 4, 5, 7, 8, 10 MRI Unilateral neck node metastasis I-III II-IV (UICC/AJCC 6th) 44.9 (1.3–69.2) 8
Zeng/2014 [25] 2003–2008 R 171/99 1, 2, 3, 4, 6, 10 MRI/PET/CT N0 II-III NR 65.1 (4.0–106.0) 7
Li/2005 [31] 1997–1998 R 88/90 1, 2, 4, 10 Palpation N0 I I-Iva (1992 FCSS) NR 6
Tang/2009 [10] 2003–2004 R 37/101 NR MRI N0 I-III I-IV (AJCC 6th) 43.0 (2.0–59.0) 6
Sun/2012 [28] 1989–2009 R 68/542 1, 2, 4, 8, 9, 10 Palpation N0 I-III NR 85.0 (3.0–254.0) 8
  1. Abbreviations: no. number; ILNSI ipsilateral lower neck sparing irradiation, ILNPI ipsilateral lower neck prophylactic irradiation, LN lymph nodes, FU follow-up, MRI magnetic resonance imaging, CT computed tomography, PET/CT positron emission tomography/computed tomography, WHO World Health Organization, AJCC American Joint Committee on Cancer, UICC Union for International Cancer Control, FCSS FuZhou Chinese Staging System, mo. month, RCT randomized controlled trial, R retrospective, RLN retropharyngeal lymph nodes, NR not reported
  2. a Matching items include:1 = sex, 2 = age, 3 = pathology, 4 = T category, 5 = N category, 6 = features of RLN, 7 = stage, 8 = histologic type (WHO), 9 = radiotherapy technique, 10 = chemoradiotherapy